Data Provided by Refinitiv. Minimum 15 minutes delayed.
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab, our lead asset which is in Phase 2 development, as well as our expanding antibody therapeutic pipeline, were discovered using Apexigen’s proprietary APXiMAB™ platform. This unique platform has enabled the discovery and development of high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Currently, one APXiMAB platform candidate is commercially available; the others are advancing through clinical development, either internally or through several licensees with our collaboration partners. Apexigen is headquartered in San Carlos, California.
June 3, 2023
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
May 24, 2023
Pyxis Oncology to Acquire Apexigen
February 27, 2023
Apexigen Announces Review of Strategic Alternatives and Restructuring